Adherence, persistence of use, and costs associated with second-generation antipsychotics for bipolar disorder

Psychiatric Services

Volumn 62, Issue 9, 2011, Pages 1032-1040

  Rascati, Karen L ^a   Richards, Kristin M ^a   Ott, Carol A ^b   Goddard, Andrew W ^c   Stafkey Mailey, Dana ^d   Alvir, Jose ^e   Sanders, Kafi N ^e   Mychaskiw, Marko ^e  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b PURDUE UNIVERSITY   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF SOUTH CAROLINA   (United States)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ARTICLE; BIPOLAR DISORDER; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; INTERNATIONAL CLASSIFICATION OF IMPAIRMENTS, DISABILITIES AND HANDICAPS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAID; MENTAL HEALTH; PATIENT COMPLIANCE; PSYCHOPHARMACOTHERAPY; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 80054832100     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/ps.62.9.pss6209_1032     Document Type: Article

References (46)

1. Kessler RC, Chiu WT, Demler O, et al.: Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Archives of General Psychiatry 62:617-627, 2005 (Pubitemid 40973437)
2. Begley CE, Annegers JF, Swann AC, et al.: The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998. Pharmacoeconomics 19:483-495, 2001 (Pubitemid 32488750)
3. McMorris BJ, Downs KE, Panish JM, et al.: Workplace productivity, employment issues, and resource utilization in patients with bipolar I disorder. Journal of Medical Economics 13:23-32, 2010
4. Kessler RC, Akiskal HS, Ames M, et al.: Prevalence and effects of mood disorders on work performance in a nationally representative sample of US workers. American Journal of Psychiatry 163:1561-1568, 2006 (Pubitemid 44465756)
5. Berk L, Hallam KT, Colom F, et al.: Enhancing medication adherence in patients with bipolar disorder. Human Psychopharmacology 25:1-16, 2010
6. Eaddy M, Grogg A, Locklear J: Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population. Clinical Therapeutics 27:263-272, 2005 (Pubitemid 40462022)
7. Sankaranarayanan J, Puumala SE: Antipsychotic use in adult ambulatory care visits by patients with mental health disorders in the United States, 1996-2003: national estimates and associated factors. Clinical Therapeutics 29:723-741, 2007 (Pubitemid 47018273)
8. Banthin JS, Meller GE: Trends in prescription drug expenditures by Medicaid enrollees. Medical Care 44:127-135, 2006
9. Hartung DM, Wisdom JP, Pollack DA, et al.: Patterns of atypical antipsychotic subtherapeutic dosing among Oregon Medicaid patients. Journal of Clinical Psychiatry 69:1540-1547, 2008
10. International Classification of Diseases, 9th Revision, Clinical Modification. Ann Arbor, Mich, Commission on Professional and Hospital Activities, 1978
11. US package insert for Abilify (aripiprazole), revised November 2009. Bristol-Myers Squibb. Available at www.abilify.com/pdf/pi.aspx?q= abilify+package+insert&ie=utf-8&oe=utf-8&aq=t&rls=org.mozilla: en-US:official&client=firefox-a
12. Fagolini A: Practical guidance for prescribing with aripiprazole in bipolar disorder. Current Medical Research and Opinion 24:2691-2702, 2008
13. Aitchison KJ, Bienroth M, Cookson J, et al.: A UK consensus on the administration of aripiprazole for the treatment of mania. Journal of Psychopharmacology 23:231, 2009
14. Citrome L, Reist C, Palmer L, et al.: Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorder. Schizophrenia Research 108:238-244, 2009
15. US package insert for Zyprexa (olanzapine), revised May 2010. Eli Lilly and Company. Available at pi.lilly.com/us/zyprexapi.pdf
16. Lambert M, Huber CG, Schacht A, et al.: Treatment of severe agitation with olanzapine in 166 patients with schizophrenia, schizoaffective, or bipolar I disorder. Pharmacopsychiatry 41:182-189, 2008
17. Citrome L, Kantrowitz JT: Olanzapine dosing above licensed range is more efficacious than lower doses: fact or fiction? Expert Review of Neurotherapeutics 9:1045-1058, 2009
18. US package insert for Seroquel (quetiapine), revised May 2010. AstraZeneca Pharmaceuticals. Available at www1.astrazeneca-us.com/pi/Seroquel. pdf
19. Citrome L, Jaffe A, Levine J, Lindenmayer JP: Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies. Journal of Clinical Psychiatry 66:1512-1516, 2005 (Pubitemid 43068688)
20. Vieta E, Goldberg JF, Mullen J, et al.: Quetiapine in the treatment of acute mania: target dose for efficacious treatment. Journal of Affective Disorders 100:S23-S31, 2007 (Pubitemid 46818459)
21. US package insert for Risperdal (risperidone), revised July 2009. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Available at www.janssen.com/sites/ default/files/shared/pdf/risperdal.pdf
22. Vietra E, Goikolea JM, Corbella B, et al.: Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study. Journal of Clinical Psychiatry 62:818-825, 2001 (Pubitemid 33104669)
23. Williams R: Optimal dosing with risperidone: updated recommendations. Journal of Clinical Psychiatry 62:282-289, 2001
24. US package insert for Geodon (ziprasidone), revised November 2009. Pfizer Inc. Available at www.pfizer.com/files/products/uspi-geodon.pdf
25. Citrome L, Jaffe A, Levine J: How dosing of ziprasidone in a state hospital system differs from product labeling. Journal of Clinical Psychiatry 7:975-982, 2009
26. Citrome L, Reist C, Palmer L, et al.: Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder. Schizophrenia Research 115:115-120, 2009
27. Cramer JA, Roy A, Burrell A, et al.: Medication compliance and persistence: terminology and definitions. Value in Health 11:44-47, 2007
28. McHorney CA, Spain CV, Alexander CM, et al.: Validity of the adherence estimator in the prediction of 9-month persistence with medication prescribed for chronic diseases: a prospective analysis of data from pharmacy claims. Clinical Therapeutics 31:2584-2607, 2009
29. Charlson, ME, Charlson RE, Peterson JC, et al.: The Charlson Comorbidity Index is adapted to predict costs of chronic disease in primary care patients. Journal of Clinical Epidemiology 61:1234-1240, 2008
30. Lage MJ, Hassan MK: The relationship between antipsychotic medication adherence and patient outcomes among individuals diagnosed with bipolar disorder: a retrospective study. Annals of General Psychiatry 8:7, 2009
31. Sajatovic M, Valenstein M, Blow FC, et al.: Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disorder 8:232-241, 2006
32. Philip NS, Mello K, Carpenter LL, et al.: Patterns of quetiapine use in psychiatric inpatients: an examination of off-label use. Annals of Clinical Psychiatry 20:15-20, 2008 (Pubitemid 351302398)
33. Stroup TS, Lieberman JA, McEvoy JP: Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. American Journal of Psychiatry 163:611-622, 2006 (Pubitemid 44464570)
34. Rascati KL, Johnsrud MT, Crismon ML, et al.: Olanzapine versus risperidone in the treatment of schizophrenia: a comparison of costs among Texas Medicaid recipients. PharmacoEconomics 21:683-697, 2003 (Pubitemid 36920634)
35. Harvey PD, Hassman H, Mao L, et al.: Cognitive functioning and acute sedative effects of risperidone and quetiapine in patients with stable bipolar I disorder: a randomized, double-blind, crossover study. Journal of Clinical Psychiatry 68:1186-1194, 2007 (Pubitemid 47395620)
36. Gianfrancesco FD, Rajagopalan K, Sajatovic M, et al.: Treatment adherence among patients with bipolar or manic disorder taking atypical and typical antipsychotics. Journal of Clinical Psychiatry 67:222-232, 2006 (Pubitemid 43357468)
37. Ying Y, Kim E, You M, et al.: Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine, or ziprasidone. Journal of Medical Economics 12:104-113, 2009
38. Fleurence RL, Dixon JM, Revicki DA: Economics of atypical antipsychotics in bipolar disorder: a review of the literature. CNS Drugs 20:591-599, 2006 (Pubitemid 43990535)
39. Merikangas KR, Akiskal HS, Angst J, et al.: Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replications. Archives of General Psychiatry 64:543-552, 2007 (Pubitemid 46718287)
40. Opolka JL, Rascati KL, Brown CM, et al.: Role of ethnicity in predicting antipsychotic medication adherence. Annals of Pharmacotherapy 37:625-630, 2003 (Pubitemid 36523052)
41. Fleck DE, Keck PE, Corey KB, Strakowski SM: Factors associated with medication adherence in African American and white patients with bipolar disorder. Journal of Clinical Psychiatry 66:646-652, 2005 (Pubitemid 40733710)
42. Horvitz-Lennon M, McGuire TG, Alegria M, et al.: Racial and ethnic disparities in the treatment of a Medicaid population with schizophrenia. Health Services Research 44:2106-2122, 2009
43. Chang K, Barnea-Goraly N, Karchemskiy A, et al.: Cortical magnetic resonance imaging findings in familial pediatric bipolar disorder. Biological Psychiatry 58:197-203, 2005 (Pubitemid 41112267)
44. Post RM, Weiss SRB: Convergences in course of illness and treatments of the epilepsies and recurrent affective disorders. Clinical EEG and Neuroscience 35:14-24, 2004 (Pubitemid 38445462)
45. Nietert PJ, Tilley BC, Zhao W, et al.: Two pharmacy interventions to improve refill persistence for chronic disease medications: a randomized, controlled trial. Medical Care 47:32-40, 2009
46. Cook PF, Emiliozzi S, Waters C, et al.: Effects of telephone counseling on antipsychotic adherence and emergency department utilization. American Journal of Managed Care 14:841-846, 2008